Breaking News
Get 40% Off 0
Is NVDA a 🟢 buy or 🔴 sell? Unlock Now

Bluebird (BLUE) Q4 Earnings Miss Estimates, Revenues In Line

By Zacks Investment ResearchStock MarketsFeb 18, 2020 09:50PM ET
www.investing.com/analysis/bluebird-blue-q4-earnings-miss-estimates-revenues-in-line-200508640
Bluebird (BLUE) Q4 Earnings Miss Estimates, Revenues In Line
By Zacks Investment Research   |  Feb 18, 2020 09:50PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
BMY
+0.64%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BLUE
+5.93%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
KDNY
+0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GH
-12.80%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

bluebird (NASDAQ:BLUE) reported a loss of $4.04 per share in the fourth quarter of 2019, wider than the Zacks Consensus Estimate of a loss of $3.81 and the year-ago quarter’s loss of $2.72.

Revenues of $10 million were in line with the Zacks Consensus Estimate. Revenues were down from $19.2 million in the year-ago quarter. The decrease mainly resulted from lower collaboration revenues under the company’s arrangement with Bristol-Myers Squibb (NYSE:BMY) .

Shares of the company have slumped 33.9% in the past year compared with the industry’s decline of 2.7%.

Quarter in Detail

R&D expenses escalated to $161.8 million in the fourth quarter of 2019 from $119.7 million a year ago due to costs incurred by the company to advance and expand the pipeline.

Selling, general and administrative (SG&A) expenses of $76.2 million were up 42.4% from the year-ago quarter to support the company’s ongoing operations, the overall growth of the pipeline and commercial-readiness activities.

2019 Results

The company’s loss per share was $14.31, wider than a loss of $10.68 in 2018.

The company generated revenues of $44.7 million, down 18.2% year over year

Pipeline Development

During the quarter, theEuropean Commission granted conditional marketing authorization to LentiGlobin for β-thalassemia, to be marketed as Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy, for patients 12 years or older with TDT, who do not have a β00 genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.

bluebird initiated its rolling Biologics License Application (BLA) submission of LentiGlobin for β-thalassemia for approval in the United States. The company is currently planning to complete the BLA submission in the second half of 2020.

In December 2019, the company announced positive top-line data from the pivotal phase II KarMMa study of ide-cel in relapsed and refractory multiple myeloma.

The company plans to submit a BLA to the FDA for ide-cel in patients with relapsed and refractory multiple myeloma in the first half of 2020, in partnership with Bristol-Myers Squibb.

The company also expects to submit a BLA to the FDA and a marketing authorization application to the European Medicines Agency for Lenti-D in patients with cerebral adrenoleukodystrophy by the end of 2020.

Zacks Rank and Other Stocks to Consider

Currently, bluebird is a Zacks Rank #2 (Buy) stock.

A few other well-placed stocks in the biotech sector are Aduro Biotech Inc. (NASDAQ:ADRO) and Guardant Health Inc. (NASDAQ:GH) all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Aduro’s loss per share estimates have narrowed from 86 cents to 77 cents for 2020 in the past 60 days.

Guardant’s loss per share estimates have narrowed from $1.18 to $1.13 for 2020 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters by 39.21%, on average.

Free: Zacks’ Single Best Stock Set to Double

Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all. This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.

See 5 Stocks Set to Double>>



Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report

bluebird bio, Inc. (BLUE): Free Stock Analysis Report

Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report

Guardant Health, Inc. (GH): Free Stock Analysis Report

Original post
Bluebird (BLUE) Q4 Earnings Miss Estimates, Revenues In Line
 

Related Articles

Bluebird (BLUE) Q4 Earnings Miss Estimates, Revenues In Line

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email